Bristol Myers reports positive Phase 2 QUINTESSENTIAL myeloma results
Bristol Myers Squibb announced positive Phase 2 registrational QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel; BMS-986393) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM).